We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye dis... Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Show more
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases...
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.075 | 1.4164305949 | 5.295 | 5.48 | 5.03 | 344965 | 5.28217673 | CS |
4 | -0.885 | -14.1486810552 | 6.255 | 6.3 | 5.03 | 456104 | 5.53798929 | CS |
12 | 1.5 | 38.7596899225 | 3.87 | 6.5476 | 3.14 | 525505 | 5.0695457 | CS |
26 | 1.07 | 24.8837209302 | 4.3 | 6.5476 | 3.1 | 440610 | 4.51380848 | CS |
52 | -0.58 | -9.74789915966 | 5.95 | 6.5476 | 1.42 | 1124533 | 3.0597732 | CS |
156 | -3.04 | -36.1474435196 | 8.41 | 11.97 | 1.42 | 919835 | 4.97274535 | CS |
260 | 0.04 | 0.750469043152 | 5.33 | 15.95 | 1.42 | 909025 | 6.80538229 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions